Prevention and treatment
In regulatory terms "prevention" usually refers to preventing bone loss, whilst "treatment" refers to decreasing fracture risk. In clinical practise this distinction is less appropriate. It is most useful to consider the indication for intervention as prevention of osteoporotic fracture whether or not a fragility fracture has occurred.
There is increasing evidence for a relatively rapid rate of treatment onset and offset for many therapeutic interventions and there has been a move away from long-term preventative strategies towards the use of shorter-term therapy for high risk individuals. There is evidence to show significant reductions in fracture rate in osteoporotic women after one years treatment. There is also evidence that the greatest fracture reduction may be acheived in women with lower bone density.
Related pages
- NICE guidance - bisphosphonates , raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE guidance - bisphosphonates , strontium ranelate , raloxifene and teriparatide for the secondary prevention of fractures in osteoporotic postmenopausal women
- Denosumab
- Treatment groups in osteoporosis
- Some principles
- Available interventions for osteoporosis
- Referral from primary care - osteoporosis
- Romosozumab in the treatment of osteoporosis
- Abaloparatide in the treatment of osteoporosis after menopause
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page